Literature DB >> 29332248

Performance of diffusion-weighted magnetic resonance imaging at 3.0T for early assessment of tumor response in locally advanced rectal cancer treated with preoperative chemoradiation therapy.

Andrea Delli Pizzi1,2, Roberta Cianci3, Domenico Genovesi4, Gianluigi Esposito5, Mauro Timpani3, Alessandra Tavoletta3, Pierluigi Pulsone3, Raffaella Basilico3, Daniela Gabrielli3, Consuelo Rosa4, Luciana Caravatta4, Monica Di Tommaso4, Massimo Caulo3,6, Antonella Filippone3.   

Abstract

PURPOSE: The purpose of the article is to determine whether changes in apparent diffusion coefficient (ADC) values of locally advanced rectal cancer (LARC) obtained 2 weeks after the beginning of chemoradiation therapy (CRT) allow to predict treatment response and whether correlate with tumor histopathologic response.
METHODS: Forty-three patients receiving CRT for LARC and 3.0T magnetic resonance imaging with diffusion-weighted sequences before treatment, 2 weeks during, and 8 weeks post the completion of CRT were included. ADC values were calculated at each time point and percentage of ADC changes at 2 weeks (ΔADC during) and 8 weeks (ΔADC post) were assessed. Data were correlated to surgical results and histopathologic tumor regression grade (TRG), according to Mandard's classification. ADC values and ΔADCs of complete responders (CR; TRG1) and non-complete responders (non-CR; TRG 2-5) were compared. Receiver-operating characteristic curve (ROC) analysis was used to assess diagnostic accuracy of ΔADC for differentiating CR from non-CR. The correlation with TRG was investigated using Spearman's rank test.
RESULTS: ΔADC during and ΔADC post were significantly higher in CR (33.9% and 57%, respectively) compared to non-CR (13.5% and 2.2%, respectively) group (p = 0.006 and p < 0.001, respectively). ROC analysis revealed the following diagnostic performances: ΔADC during: AUC 0.78 (0.08), p = 0.004, cut-off 20.6% (sensitivity 75% and specificity 76.5%); ΔADC post: AUC 0.94 (0.04), p ≤ 0.001, cut-off 22% (sensitivity 95% and specificity 82.4%). Significant moderate and good negative correlation was found between ΔADC during and ΔADC post and TRG (r = - 0.418, p = 0.007; r = - 694, p ≤ 0.001, respectively).
CONCLUSION: ΔADC at 2 weeks after the beginning of CRT is a reliable tool to early assess treatment response.

Entities:  

Keywords:  Chemoradiation treatment response; Complete responders; Diffusion-weighted imaging; Locally advanced rectal cancer; Magnetic resonance

Mesh:

Year:  2018        PMID: 29332248     DOI: 10.1007/s00261-018-1457-8

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  10 in total

1.  Multiparametric MRI of rectal cancer-repeatability of quantitative data: a feasibility study.

Authors:  Bengi Gürses; Emre Altınmakas; Medine Böge; M Serhat Aygün; Onur Bayram; Emre Balık
Journal:  Diagn Interv Radiol       Date:  2020-03       Impact factor: 2.630

2.  Volume Delineation in Cervical Cancer With T2 and Diffusion-weighted MRI: Agreement on Volumes Between Observers.

Authors:  Consuelo Rosa; Andrea Delli Pizzi; Antonietta Augurio; Luciana Caravatta; Monica DI Tommaso; Erica Mincuzzi; Sebastiano Cinalli; Raffaella Basilico; Annamaria Porreca; Marta DI Nicola; Domenico Genovesi
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  The apparent diffusion coefficient is a useful biomarker in predicting treatment response in patients with locally advanced rectal cancer.

Authors:  Mayra Evelia Jiménez de Los Santos; Juan Armando Reyes-Pérez; Rosa Martha Sandoval-Nava; José Luis Villalobos-Juárez; Yolanda Villaseñor-Navarro; Itzel Vela-Sarmiento; Isabel Sollozo-Dupont
Journal:  Acta Radiol Open       Date:  2020-09-15

4.  Pretreatment Apparent Diffusion Coefficient Cannot Predict Histopathological Features and Response to Neoadjuvant Radiochemotherapy in Rectal Cancer: A Meta-Analysis.

Authors:  Alexey Surov; Maciej Pech; Maciej Powerski; Katja Woidacki; Andreas Wienke
Journal:  Dig Dis       Date:  2021-03-04       Impact factor: 2.404

5.  Diffusion-weighted imaging and diffusion kurtosis imaging for early evaluation of the response to docetaxel in rat epithelial ovarian cancer.

Authors:  Su-Juan Yuan; Tian-Kui Qiao; Jin-Wei Qiang
Journal:  J Transl Med       Date:  2018-12-05       Impact factor: 5.531

Review 6.  Quantitative Magnetic Resonance Imaging for Biological Image-Guided Adaptive Radiotherapy.

Authors:  Petra J van Houdt; Yingli Yang; Uulke A van der Heide
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

7.  T2 relaxation time for the early prediction of treatment response to chemoradiation in locally advanced rectal cancer.

Authors:  Yuxi Ge; Yanlong Jia; Xiaohong Li; Weiqiang Dou; Zhong Chen; Gen Yan
Journal:  Insights Imaging       Date:  2022-07-07

8.  Renal cell carcinoma with venous extension: prediction of inferior vena cava wall invasion by MRI.

Authors:  Lisa C Adams; Bernhard Ralla; Yi-Na Y Bender; Keno Bressem; Bernd Hamm; Jonas Busch; Florian Fuller; Marcus R Makowski
Journal:  Cancer Imaging       Date:  2018-05-03       Impact factor: 3.909

9.  MRI-based clinical-radiomics model predicts tumor response before treatment in locally advanced rectal cancer.

Authors:  Andrea Delli Pizzi; Antonio Maria Chiarelli; Piero Chiacchiaretta; Martina d'Annibale; Pierpaolo Croce; Consuelo Rosa; Domenico Mastrodicasa; Stefano Trebeschi; Doenja Marina Johanna Lambregts; Daniele Caposiena; Francesco Lorenzo Serafini; Raffaella Basilico; Giulio Cocco; Pierluigi Di Sebastiano; Sebastiano Cinalli; Antonio Ferretti; Richard Geoffrey Wise; Domenico Genovesi; Regina G H Beets-Tan; Massimo Caulo
Journal:  Sci Rep       Date:  2021-03-08       Impact factor: 4.996

10.  Diffusion-Weighted Magnetic Resonance Imaging of 103 Patients with Rectal Adenocarcinoma Identifies the Apparent Diffusion Coefficient as an Imaging Marker for Tumor Invasion and Regional Lymph Node Involvement.

Authors:  Jaromir Kargol; Wojciech Rudnicki; Jakub Kenig; Justyna Filipowska; Ewa Kaznowska; Tomasz Kluz; Wiesław Guz; Elżbieta Łuczyńska
Journal:  Med Sci Monit       Date:  2021-12-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.